Terms: = Pancreatic cancer AND NRG1, ENSG00000157168, 3084, SMDF, NDF, HRGA, HRG1, HGL, GGF2, GGF, ARIA AND Treatment
22 results:
1. pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection.
Brozos-Vázquez E; Toledano-Fonseca M; Costa-Fraga N; García-Ortiz MV; Díaz-Lagares Á; Rodríguez-Ariza A; Aranda E; López-López R
Cancer Treat Rev; 2024 Apr; 125():102719. PubMed ID: 38490088
[TBL] [Abstract] [Full Text] [Related]
2. Real-world outcomes associated with afatinib use in patients with solid tumors harboring nrg1 gene fusions.
Liu SV; Frohn C; Minasi L; Fernamberg K; Klink AJ; Gajra A; Savill KMZ; Jonna S
Lung Cancer; 2024 Feb; 188():107469. PubMed ID: 38219288
[TBL] [Abstract] [Full Text] [Related]
3. pancreatic cancer Action Network's SPARK: A Cloud-Based Patient Health Data and Analytics Platform for pancreatic cancer.
Abdilleh K; Khalid O; Ladnier D; Wan W; Seepo S; Rupp G; Corelj V; Worman ZF; Sain D; DiGiovanna J; Press B; Chandrashekhar S; Collisson E; Cui KY; Maitra A; Rejto PA; White KP; Matrisian L; Doss S
JCO Clin Cancer Inform; 2024 Jan; 8():e2300119. PubMed ID: 38166233
[TBL] [Abstract] [Full Text] [Related]
4. PARPis and Other Novel, Targeted Therapeutics in pancreatic Adenocarcinoma.
Chapin WJ; Reiss KA
Hematol Oncol Clin North Am; 2022 Oct; 36(5):1019-1032. PubMed ID: 36154785
[TBL] [Abstract] [Full Text] [Related]
5. Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by nrg1 Gene Rearrangements.
Schram AM; Odintsov I; Espinosa-Cotton M; Khodos I; Sisso WJ; Mattar MS; Lui AJW; Vojnic M; Shameem SH; Chauhan T; Torrisi J; Ford J; O'Connor MN; Geuijen CAW; Schackmann RCJ; Lammerts van Bueren JJ; Wasserman E; de Stanchina E; O'Reilly EM; Ladanyi M; Drilon A; Somwar R
Cancer Discov; 2022 May; 12(5):1233-1247. PubMed ID: 35135829
[TBL] [Abstract] [Full Text] [Related]
6. First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy.
Diamond JR; Boni V; Lim E; Nowakowski G; Cordoba R; Morillo D; Valencia R; Genvresse I; Merz C; Boix O; Frigault MM; Greer JM; Hamdy AM; Huang X; Izumi R; Wong H; Moreno V
Clin Cancer Res; 2022 Apr; 28(7):1285-1293. PubMed ID: 35046056
[TBL] [Abstract] [Full Text] [Related]
7. The potential targeted drugs for fusion genes including nrg1 in pancreatic cancer.
Umemoto K; Sunakawa Y
Crit Rev Oncol Hematol; 2021 Oct; 166():103465. PubMed ID: 34454058
[TBL] [Abstract] [Full Text] [Related]
8. [Ductal adenocarcinoma of the pancreas: subtypes and molecular pathology].
Schlitter AM; Konukiewitz B; Kasajima A; Reichert M; Klöppel G
Pathologe; 2021 Sep; 42(5):464-471. PubMed ID: 34402977
[TBL] [Abstract] [Full Text] [Related]
9. Early-Onset Pancreas cancer: Clinical Descriptors, Genomics, and Outcomes.
Varghese AM; Singh I; Singh R; Kunte S; Chou JF; Capanu M; Wong W; Lowery MA; Stadler ZK; Salo-Mullen E; Saadat LV; Wei AC; Reyngold M; Basturk O; Benayed R; Mandelker D; Iacobuzio-Donahue CA; Kelsen DP; Park W; Yu KH; O'Reilly EM
J Natl Cancer Inst; 2021 Sep; 113(9):1194-1202. PubMed ID: 33755158
[TBL] [Abstract] [Full Text] [Related]
10. Identification of tumors with nrg1 rearrangement, including a novel putative pathogenic UNC5D-nrg1 gene fusion in prostate cancer by data-drilling a de-identified tumor database.
Ptáková N; Martínek P; Holubec L; Janovský V; Vančurová J; Grossmann P; Navarro PA; Rodriguez Moreno JF; Alaghehbandan R; Hes O; Májek O; Pešek M; Michal M; Ondič O
Genes Chromosomes Cancer; 2021 Jul; 60(7):474-481. PubMed ID: 33583086
[TBL] [Abstract] [Full Text] [Related]
11. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract] [Full Text] [Related]
12. nrg1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.
Laskin J; Liu SV; Tolba K; Heining C; Schlenk RF; Cheema P; Cadranel J; Jones MR; Drilon A; Cseh A; Gyorffy S; Solca F; Duruisseaux M
Ann Oncol; 2020 Dec; 31(12):1693-1703. PubMed ID: 32916265
[TBL] [Abstract] [Full Text] [Related]
13. How I treat pancreatic cancer.
Taieb J; Abdallah R
ESMO Open; 2020 Aug; 4(Suppl 2):e000818. PubMed ID: 32817138
[TBL] [Abstract] [Full Text] [Related]
14. The Unmet Needs of the Diagnosis, Staging, and treatment of Gastrointestinal Tumors.
Halama N; Haberkorn U
Semin Nucl Med; 2020 Sep; 50(5):389-398. PubMed ID: 32768003
[TBL] [Abstract] [Full Text] [Related]
15. Oncogenic nrg1 Fusions: A New Hope for Targeted Therapy in pancreatic cancer.
Aguirre AJ
Clin Cancer Res; 2019 Aug; 25(15):4589-4591. PubMed ID: 31164372
[TBL] [Abstract] [Full Text] [Related]
16.
Jones MR; Williamson LM; Topham JT; Lee MKC; Goytain A; Ho J; Denroche RE; Jang G; Pleasance E; Shen Y; Karasinska JM; McGhie JP; Gill S; Lim HJ; Moore MJ; Wong HL; Ng T; Yip S; Zhang W; Sadeghi S; Reisle C; Mungall AJ; Mungall KL; Moore RA; Ma Y; Knox JJ; Gallinger S; Laskin J; Marra MA; Schaeffer DF; Jones SJM; Renouf DJ
Clin Cancer Res; 2019 Aug; 25(15):4674-4681. PubMed ID: 31068372
[TBL] [Abstract] [Full Text] [Related]
17.
Heining C; Horak P; Uhrig S; Codo PL; Klink B; Hutter B; Fröhlich M; Bonekamp D; Richter D; Steiger K; Penzel R; Endris V; Ehrenberg KR; Frank S; Kleinheinz K; Toprak UH; Schlesner M; Mandal R; Schulz L; Lambertz H; Fetscher S; Bitzer M; Malek NP; Horger M; Giese NA; Strobel O; Hackert T; Springfeld C; Feuerbach L; Bergmann F; Schröck E; von Kalle C; Weichert W; Scholl C; Ball CR; Stenzinger A; Brors B; Fröhling S; Glimm H
Cancer Discov; 2018 Sep; 8(9):1087-1095. PubMed ID: 29802158
[TBL] [Abstract] [Full Text] [Related]
18. Response to ERBB3-Directed Targeted Therapy in
Drilon A; Somwar R; Mangatt BP; Edgren H; Desmeules P; Ruusulehto A; Smith RS; Delasos L; Vojnic M; Plodkowski AJ; Sabari J; Ng K; Montecalvo J; Chang J; Tai H; Lockwood WW; Martinez V; Riely GJ; Rudin CM; Kris MG; Arcila ME; Matheny C; Benayed R; Rekhtman N; Ladanyi M; Ganji G
Cancer Discov; 2018 Jun; 8(6):686-695. PubMed ID: 29610121
[No Abstract] [Full Text] [Related]
19. Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3.
Le Clorennec C; Bazin H; Dubreuil O; Larbouret C; Ogier C; Lazrek Y; Garambois V; Poul MA; Mondon P; Barret JM; Mathis G; Prost JF; Pèlegrin A; Chardès T
Mol Cancer Ther; 2017 Jul; 16(7):1312-1323. PubMed ID: 28507002
[TBL] [Abstract] [Full Text] [Related]
20. Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease-Associated Colorectal cancers.
Robles AI; Traverso G; Zhang M; Roberts NJ; Khan MA; Joseph C; Lauwers GY; Selaru FM; Popoli M; Pittman ME; Ke X; Hruban RH; Meltzer SJ; Kinzler KW; Vogelstein B; Harris CC; Papadopoulos N
Gastroenterology; 2016 Apr; 150(4):931-43. PubMed ID: 26764183
[TBL] [Abstract] [Full Text] [Related]
[Next]